Table 1. Characterization of blank NPs and drug encapsulated NPs.
Groups | Particle size (nm) | Polydispersity | Zeta potential (mV) |
---|---|---|---|
FA-PEG-PLGA NPs | 134.71±6.42 | 0.165±0.015 | −26.12±1.23 |
CDDP-FA-NPs | 149.38±9.04 | 0.187±0.018 | −22.48±0.97 |
PTX-FA-NPs | 161.81±6.97 | 0.172±0.025 | −23.51±1.34 |
Co-FA-NPs (CDDP: PTX = 2:1) | 171.36±8.67 | 0.133±0.008 | −21.50±0.88 |
Co-FA-NPs (CDDP: PTX = 1:1) | 177.23±10.79 | 0.151±0.013 | −22.78±1.16 |
Co-FA-NPs (CDDP: PTX = 1:2) | 185.94±7.43 | 0.158±0.012 | −24.68±1.21 |
Co-NPs (CDDP: PTX = 1:2) | 176.56±4.83 | 0.161±0.016 | −23.07±0.98 |
Diameter and zeta potential were determined by DLS. Three batches of samples (1 mg/mL) were prepared by directly dissolving NPs in distilled water, then sonication 5 min.